A meta-analysis revealed that dipeptidyl peptidase IV inhibitor (DPP-4) inhibitors were significantly more effective than other oral antihyperglycemic drugs at reducing GV in patients with type 2 diabetes [39]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.